Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (12918)	1/1/1998 9:58:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Actually, a profit by the end of this year would seem to preclude a secondary which was alluded to in Jesse Eisinger's article. Thus, a profit in this year, even if it's just $0.03 whould be of import. There will be lots of good news in 1998, and I suspect that a $0.03 prifit in 4Q would require the sale of some Panretin, which would mean a very quick launch. I think that when the street begins to seen earning projections based on approved products, they will begin to see LGND's potential. All three retinoids (Targretin, Panretin, and ALRT1550) will be in trials for a wide range of cancers, and the entire market wil be quite large. The cheat sheet of Fall '96 lists over 1/2 million new cancer patients in the indications targeted by LGND, as well as 1.2 million new HIV patients. Of course the number who have already been diagnosed is also considerable and LGND gets the lion's share of income from the various cancers as well as HIV patients.